AI Article Synopsis
- - The POLARIX trial found that pola-R-CHP offers better progression-free survival than R-CHOP for patients with untreated intermediate- to high-risk DLBCL.
- - A survey of 174 clinicians, primarily from academic centers in the U.S., revealed that 70% would not switch to pola-R-CHP due to its limited PFS benefits and high costs.
- - There was significant variation in how clinicians interpreted the trial results and their strategies for applying pola-R-CHP in practice.
Article Abstract
In the POLARIX trial, pola-R-CHP demonstrated improved progression-free survival (PFS) compared to R-CHOP in untreated intermediate- to high-risk DLBCL. We surveyed practicing clinicians regarding their interpretation of POLARIX, including impressions of efficacy, safety, and cost. Of 174 respondents, most from academic centers (82%) in the United States (57%), 70% stated they would not replace R-CHOP with pola-R-CHP due to insufficient PFS difference, lack of overall survival benefit, and excessive cost. Respondents not recommending pola-R-CHP expressed concerns about financial implications for both society and patients. We observed considerable heterogeneity in both study interpretation and plans for real-world implementation of pola-R-CHP.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422021 | PMC |
| http://dx.doi.org/10.1002/jha2.505 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and Safety of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Previously Untreated Diffuse Large B-Cell Lymphoma: A Real-World, Multi-Center, Retrospective Cohort Study.
Hematol Oncol
January 2025
Department of Lymphoma, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China.
Polatuzumab vedotin plus R-CHP (Pola-R-CHP) is approved as a new standard first-line therapy for diffuse large B-cell lymphoma (DLBCL) based on the POLARIX trial. However, real-world data on its efficacy and safety in unselected patients is lacking. We conducted a retrospective cohort study to evaluate Pola-R-CHP versus R-CHOP outcomes in routine clinical practice in China.
View Article and Find Full Text PDFReal-world outcomes of diffuse large B-cell lymphoma treated with frontline R-CHOP(-like) regimens in an Asian multi-ethnic population.
Ann Hematol
December 2024
Division of Medical Oncology, National Cancer Centre Singapore, 30 Hospital Blvd, Singapore, 168583, Singapore.
Background: Recent breakthrough advances in the treatment of DLBCL, such as the antibody-drug conjugate polatuzumab vedotin, have yielded clinical survival benefit over rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for the first time in 20 years since the advent of the rituximab era. We thus examine the outcomes of standard immunochemotherapy for DLBCL in our multi-ethnic Asian population, so as to determine the real-world clinical need to adopt new therapeutics in this disease entity.
Methods: We conducted a retrospective study involving patients (n = 1071) diagnosed with DLBCL at the National Cancer Centre Singapore from 2010 to 2022, and treated with first-line rituximab-based regimens.
How I treat older patients with relapsed/refractory diffuse large B-cell lymphoma.
Blood
January 2025
Division of Hematology/Oncology, Department of Medicine, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY.
Article Synopsis
- * New treatment options are emerging; however, determining which are safe and effective for older patients, especially in cases of relapse, remains complicated and requires careful assessments.
- * The article outlines strategies for managing older adults with relapsed DLBCL, including advanced therapies like CAR-T cell therapy and other innovative treatments tailored for this age group.
The current landscape of frontline large B-cell lymphoma trials.
Blood
January 2025
Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Article Synopsis
- - At least 25-35% of patients with large B cell lymphoma (LBCL) do not respond to current standard treatments like R-CHOP, prompting the need for better options.
- - A new treatment regimen (Pola-R-CHP) is gaining attention, and there are currently 15 promising randomized trials exploring diverse new therapies for frontline LBCL.
- - These trials vary in their treatment methods and patient selection, presenting potential challenges in interpreting results and choosing the best treatment options if multiple trials prove successful.
Spotlight on polatuzumab vedotin: new standards for diffuse large B-cell lymphoma?
Haematologica
September 2024
Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York.
Article Synopsis
- - Despite advancements in treating diffuse large B-cell lymphoma (DLBCL), about 35% of patients still experience relapse or don't respond to initial chemotherapy, highlighting a need for better treatment options.
- - Polatuzumab vedotin, an anti-CD79b antibody linked to a powerful inhibitor, has shown promising results in clinical trials, particularly when combined with other standard treatments, improving survival rates for both newly diagnosed and relapsed patients.
- - Health authorities have approved polatuzumab vedotin for use in treating both previously untreated and relapsed/refractory DLBCL, and ongoing studies are exploring further combinations and assessing potential side effects.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!